健康活动方案——由非专业咨询员在基层医疗中提供的抑郁症简短心理治疗——的持续有效性与成本效益:一项随机对照试验的12个月随访
在印度城郊和农村基层医疗中,筛选出中重度抑郁症的18-65岁就诊者,随机分为健康活动方案(HAP)联合强化常规照护(EUC)组(n=247)或单独EUC组(n=248)。HAP组在治疗结束后12个月内维持了终点时的获益,抑郁症状严重度低于EUC组(BDI-II调整均差=-4.45),缓解率更高(aPR=1.36),且HAP联合EUC具有成本效益优势。
要点
- HAP组在12个月随访时BDI-II评分低于EUC组(调整均差=-4.45),缓解率更高(aPR=1.36)。
- HAP组在恢复、任意应答、最小临床重要差异报告率等多数次要结局上优于EUC组。
- HAP联合EUC相比单独EUC具有成本效益优势,在支付意愿阈值Intl$16,060/质量调整生命年下95%概率具有成本效益。
核心结论
- HAP在治疗结束时相对于EUC的优势在12个月内基本稳定,且由患者激活水平所中介。
- 从覆盖公共资助医疗服务及患者和家庭生产力影响的视角看,HAP以更低成本提供了更好结局。
研究设计与样本
- 随机对照试验,在印度城郊和农村基层医疗中纳入18-65岁、PHQ-9筛查为中重度至重度抑郁症的就诊者。
- 参与者随机分为HAP联合EUC组(n=247)或单独EUC组(n=248),3个月评估完成率95%,12个月完成率91%。
主要发现
- HAP组在3至12个月间BDI-II平均评分维持不变(差值=-0.34;95%CI -2.37, 1.69;p=0.74)。
- 12个月时HAP组BDI-II评分低于EUC组(调整均差=-4.45;95%CI -7.26, -1.63;p=0.002),缓解率更高(aPR=1.36;95%CI 1.15, 1.61;p<0.009)。
- HAP组在恢复(aPR=1.98;95%CI 1.29, 3.03;p=0.002)、任意应答(aPR=1.45;95%CI 1.27, 1.66;p<0.001)、报告最小临床重要差异(aPR=1.42;95%CI 1.17, 1.71;p<0.001)方面优于EUC组,报告自杀行为可能性更低(aPR=0.71;95%CI 0.51, 1.01;p=0.06)。
- HAP联合EUC对12个月时WHO残疾评估量表评分有边缘效应(aPR=-1.58;95%CI -3.33, 0.17;p=0.08);无法工作天数和女性亲密伴侣暴力两个结局在两组间无统计学显著差异。
- 3个月时患者报告的行为激活水平中介了HAP对12个月抑郁评分的影响(β=-2.62;95%CI -3.28, -1.97;p<0.001)。
关键数值与推荐
- HAP联合EUC相比单独EUC具有成本效益优势,成本更低且结局更好;在支付意愿阈值为Intl$16,060(相当于果阿人均GDP)/质量调整生命年时,从卫生系统视角有95%概率具有成本效益。
- 严重不良事件不常见,且两组患病率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无法评估随机化后3至12个月两个结局评估时间点之间可能发生的缓解和复发。
- 未考虑或评估行为激活以外的其他中介因素的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Healthy Activity Programme (HAP), a brief behavioural intervention delivered by lay counsellors, enhanced remission over 3 months among primary care attendees with depression in peri-urban and rural settings in India. We evaluated the sustainability of the effects after treatment termination, the cost-effectiveness of HAP over 12 months, and the effects of the hypothesized mediator of activation on clinical outcomes. METHODS AND FINDINGS: Primary care attendees aged 18-65 years screened with moderately severe to severe depression on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP plus enhanced usual care (EUC) (n = 247) or EUC alone (n = 248), of whom 95% completed assessments at 3 months, and 91% at 12 months. Primary outcomes were severity on the Beck Depression Inventory-II (BDI-II) and remission on the PHQ-9. HAP participants maintained the gains they showed at the end of treatment through the 12-month follow-up (difference in mean BDI-II score between 3 and 12 months = -0.34; 95% CI -2.37, 1.69; p = 0.74), with lower symptom severity scores than participants who received EUC alone (adjusted mean difference in BDI-II score = -4.45; 95% CI -7.26, -1.63; p = 0.002) and higher rates of remission (adjusted prevalence ratio [aPR] = 1.36; 95% CI 1.15, 1.61; p < 0.009). They also fared better on most secondary outcomes, including recovery (aPR = 1.98; 95% CI 1.29, 3.03; p = 0.002), any response over time (aPR = 1.45; 95% CI 1.27, 1.66; p < 0.001), higher likelihood of reporting a minimal clinically important difference (aPR = 1.42; 95% CI 1.17, 1.71; p < 0.001), and lower likelihood of reporting suicidal behaviour (aPR = 0.71; 95% CI 0.51, 1.01; p = 0.06). HAP plus EUC also had a marginal effect on WHO Disability Assessment Schedule score at 12 months (aPR = -1.58; 95% CI -3.33, 0.17; p = 0.08); other outcomes (days unable to work, intimate partner violence toward females) did not statistically significantly differ between the two arms. Economic analyses indicated that HAP plus EUC was dominant over EUC alone, with lower costs and better outcomes; uncertainty analysis showed that from this health system perspective there was a 95% chance of HAP being cost-effective, given a willingness to pay threshold of Intl$16,060-equivalent to GDP per capita in Goa-per quality-adjusted life year gained. Patient-reported behavioural activation level at 3 months mediated the effect of the HAP intervention on the 12-month depression score (β = -2.62; 95% CI -3.28, -1.97; p < 0.001). Serious adverse events were infrequent, and prevalence was similar by arm. We were unable to assess possible episodes of remission and relapse that may have occurred between our outcome assessment time points of 3 and 12 months after randomisation. We did not account for or evaluate the effect of mediators other than behavioural activation. CONCLUSIONS: HAP's superiority over EUC at the end of treatment was largely stable over time and was mediated by patient activation. HAP provides better outcomes at lower costs from a perspective covering publicly funded healthcare services and productivity impacts on patients and their families. TRIAL REGISTRATION: ISRCTN registry ISRCTN95149997.
引用
- Weobong B, Weiss HA, McDaid D, et al. Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial. PLoS Med. 2017. PMID: 28898283. doi:10.1371/journal.pmed.1002385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。